Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 2, 2004 - Issue 5
Submit an article Journal homepage
64
Views
32
CrossRef citations to date
0
Altmetric
Drug Evaluation

Dexamethasone-eluting stent: an anti-inflammatory approach to inhibit coronary restenosis

Xiaoshun Liu Department of Cardiology, University Hospitals Leuven, Belgium. [email protected]
,
Ivan De Scheerder Department of Cardiology, University Hospitals Leuven, Belgium. [email protected]
&
Walter Desmet Cardiac Catheterization Laboratory, University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. [email protected]
Pages 653-660 | Published online: 10 Jan 2014

References

  • Gruntzig A. Transluminal dilation of coronary artery stenosis. Lancet 1, 263 (1978).
  • American Heart Association. 2002 Heart and Stroke Statistical Update. American Heart Association, TX, USA (2001).
  • Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler. Thromb. Vasc. Biol. 22(11), 1769–1776 (2002).
  • ••Overview of the pathophysiology ofrestenosis explaining the central role of inflammation.
  • Donners MM, Daemen MJ, Cleutjens KB, Heeneman S. Inflammation and restenosis: implications for therapy. Ann. Med 35(7), 523–531 (2003).
  • ••Review of mechanisms involved inrestenosis with a focus on the role of inflammation.
  • Tanaka H, Sukhova GK, Swanson SJ et al. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation 88,1788–1803 (1993).
  • Walpola PL, Gotlieb AT, Cybulsky MI, Langille L. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress. Arterioscler. Thromb. Vasa BioL 15,2–10 (1995).
  • Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits: coupled inhibitory effects of heparin. Arterioscler. Thromb. Vasc. Biol. 16,1312–1318 (1996).
  • Welt FG, Tso C, Edelman ER et al. Leukocyte recruitment and expression of chemokines following different forms of vascular injury. Vasc. Med. 8(1), 1–7 (2003).
  • Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 105(25), 2974–2980 (2002).
  • •Documents the inflammatory response to coronary stenting in humans.
  • Jorgensen L, Grothe AG, Groves HM et al Sequence of cellular responses in rabbit aortas following one and two injuries with a balloon catheter. Br. J. Exp. PathoL 69, 473–486 (1988).
  • Richardson M, Hatton MW, Buchanan MR, Moore S. Wound healing in the media of the normolipemic rabbit carotid artery injured by air drying or by balloon catheter de-endothelialization. Am. J. Pathol. 137, 1453–1465 (1990).
  • Koch MM, De Meyer GR, Jacob WA, Bult H, Herman AG. Triphasic sequence of neointimal formation in the cuffed carotid artery of the rabbit. Arterioscler. Thromb. 12,1447–1457 (1992).
  • Lloyd AR, Oppenheim JJ. Poly's lament: the neglected role of the polymorphonudear neutrophil in the afferent limb of the immune response. Immunol. Today 13,169–172 (1992).
  • Cole CW, Makhoul RG, McCann RL et al. A neutrophil derived factor(s) stimulates [314fthymidine incorporation by vascular smooth muscle cells in vitro. Clin. Invest. Med. 11,62–67(1988).
  • Song L, Leung C, Schindler C. Lymphocytes are important in early atherosclerosis. J. Clin. Invest. 108, 251–259 (2001).
  • Zhu B, Reardon CA, Getz GS, Hui DY. Both apolipoprotein E and immune deficiency exacerbate neointimal hyperplasia after vascular injury in mice. Arterioscler. Thromb. Vasc. Biol. 22, 450–455 (2002).
  • Shi Y, O'Brien JE, Fard A et al. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 94,1655–1664 (1996).
  • •Study of vascular fibroblasts in the process of arterial repair.
  • Rogers C, Edelman ER, Simon DI. A mAb to the 132-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc. Natl Acad. Sci. USA 95,10134–10139 (1998).
  • Mod E, Komori K, Yamaoka T et al. Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits. Circulation 105,12905–10133 (2002).
  • Schober A, Manka D, von Hundelshausen P et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 106,1523–1529 (2002).
  • Cipollone F, Marini M, Fazia M et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler. Thromb. Vasc. Biol. 21, 327–334 (2001).
  • Roque M, Kim WJ, Gazdoin M et al. CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler. Thromb. Vasc. Biol. 22, 554–559 (2002).
  • Horvath C, Welt FG, Nedelman M et al. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ. Res. 90,488–494 (2002).
  • Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules. NF-K-B and cytokine-inducible enhancers. Fed. Am. Soc. Exp. Biol. 9,899–909 (1995).
  • Baeuerle PA, Henkel T. Function and activation of NE-KB in the immune system. Ann. Rev. Immunol12, 141–179 (1994).
  • Collins T, Cybulsky MI. NE-KB: pivotal mediator or innocent bystander in atherogenesis? J. Clin. Invest. 107, 255–264 (2001).
  • Landry DB, Couper LL, Bryant SR, Lindner V. Activation of the NE-KB and I-KB system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am. J. Pathol. 151,1085–1095 (1997).
  • Wainwright CL, Miller AM, Wadsworth RM. Inflammation as a key event in the development of neointima following vascular balloon injury. Clin. Exp. Pharmacol. Physiol. 28,891–895 (2001).
  • ••Review of the key role that leukocytesplay in the development of neointima.
  • Manka DR, Wiegman P, Din S et al. Arterial injury increases expression of inflammatory adhesion molecules in the carotid arteries of apolipoprotein-E-deficient mice. J. Vasc. Res. 36,372–378 (1999).
  • Bishop GG, McPherson JA, Sanders JM et al. Selective a(v)13(3)-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 103, 1906–1911 (2001).
  • Cato AC, Wade E. Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioessays 18(5), 371–378 (1996).
  • •Review of the molecular mechanisms of the anti-inflammatory action of glucocorticoids.
  • De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J. Neuroimmunol. 109(1), 16–22 (2000).
  • Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of 1K-B in mediation of immunosuppression by glucocorticoids. Science 270, 283–286 (1995).
  • Wissink S, Van Heerde EC, Van Der Burg B, Van Der Saag PT. A dual mechanism mediates repression of NF-K-B activity by glucocorticoids. MoL EndocrinoL 12, 355–363 (1998).
  • Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 232, 977–980 (1986).
  • Mukaida N, Zachariae CC, Gusella GL, Matsushima K. Dexamethasone inhibits the induction of monocyte chemotactic-activating factor production by IL-1 or tumor necrosis factor." ImmunoL 146(4), 1212–1215 (1991).
  • Vanden Berghe W, Francesconi E, De Bosscher K, Resche-Rigon M, Haegeman G. Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-KB-dependent mechanism. MoL Pharmacol. 56,797–806 (1999).
  • Aziz KE, Wakefield D. Modulation of endothelial cell expression of ICAM-1, E-selectin, and VCAM-1 by P-estradiol, progesterone, and dexamethasone. Cell. ImmunoL 167(1), 79–85 (1996).
  • Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the anti-inflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc. Natl Acad. Sci. USA 89(21), 9991–9995 (1992).
  • Ray KP, Farrow S, Daly M, Talabot F, Searle N. Induction of the E-selectin promoter by interleukin-1 and tumour necrosis factor-a, and inhibition by glucocorticoids. Biochem. J. 328, 707–715 (1997).
  • Auphan N, Didonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-K-B activity through induction of 1K-B synthesis. Science 270, 286–290 (1995).
  • Adcock IM, Nasuhara Y, Stevens DA, Barnes PJ. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targeting of NF-KB and lack of I-KB involvement. Br. J. PharmacoL 127, 1003–1011 (1999).
  • Heyderman RS, Klein NJ, Daramola OA, Levin M. Modulation of the endothelial procoagulant response to lipopolysaccharide and tumour necrosis factor-a in vitro: the effects of dexamethasone, pentoxifylline, iloprost and a polyclonal antihuman IL-1 a-antibody. Inigam. Res. 44(7), 275–280 (1995).
  • Davenpeck KL, Zagorski J, Schleimer RP, Bochner BS. Lipopolysaccharide-induced leukocyte rolling and adhesion in the rat mesenteric microcirculation: regulation by glucocorticoids and role of cytokines. J. ImmunoL 161(12), 6861–6870 (1998).
  • Wingett D, Forcier K, Nielson CP. Glucocorticoid-mediated inhibition of RANTES expression in human T-lymphocytes. FEBS Lett. 398(2–3), 308–311 (1996).
  • Kwon OJ, Jose PJ, Robbins RA, Schall TJ, Williams TJ, Barnes PJ. Glucocorticoid inhibition of RANTES expression in human lung epithelial cells. Am. J. Respir. Cell. MoL Biol. 12(5), 488–496 (1995).
  • Voisard R, Seitzer U, Baur R et al. Corticosteroid agents inhibit proliferation of smooth muscle cells from human atherosclerotic arteries in vitro. Int. J. CardioL 43(3), 257–267 (1994).
  • Reil TD, Kashyap VS, Sarkar R, Freishlag J, Gelabert HA. Dexamethasone inhibits the phosphorylation of retinoblastoma protein in the suppression of human vascular smooth muscle cell proliferation. J. Surg. Res. 92(1),108-113 (2000).
  • Pross C, Farooq MM, Angle N et al. Dexamethasone inhibits vascular smooth muscle cell migration via modulation of matrix metalloproteinase activity. J. Surg. Res. 102(2), 57–62 (2002).
  • Stone GW, Rutherford BD, McConahay DR et al. A randomized trial of corticosteroids for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty. Cathet. Cardiovasc. Diagn. 18(4), 227–231 (1989).
  • Pepine CJ, Hirshfeld JW, Macdonald RG et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. Circulation 81(6), 1753–1752 (1999).
  • Lee CW, Chae JK, Lim HY et al. Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am. Heart J. 138(1 Pt 1), 60–63 (1999).
  • Versaci F, Gaspardone A, Tomai F et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation study. IMmunosuppressive therapy for the Prevention of REStenosis after coronary artery Stent implantation (IMPRESS Study). J. Am. Coll. CardioL 40(11), 1935–1942 (2002).
  • Villa AE, Guzman LA, Chen W, Golomb G, Levy RJ, Topol EJ. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty.' Clin. Invest. 93(3), 1243–1249 (1994).
  • Muller DW, Golomb G, Gordon D, Levy RJ. Site-specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation. Caron. Artery Dis. 5(5), 435–442 (1994).
  • Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J. Am. Coll. CardioL 29(4), 808–816 (1997).
  • Strecker EP, Gabelmann A, Boos I et al. Effect on intimal hyperplasia of dexamethasone released from coated metal stents compared with noncoated stents in canine femoral arteries. Cardiovasc. Intervent. RadioL 21(6), 487–496 (1998).
  • De Scheerder I, Wang K, Wilczek K et al. Local methylprednisolone inhibition of foreign body response to coated intracoronary stents. Caron. Artery Dis. 7(2), 161–166 (1996).
  • Huang Y, Wang L, Verweire I et al. Optimization of local methylprednisolone delivery to inhibit inflammatory reaction and neointimal hyperplasia of coated coronary stents. J. Invasive CardioL 14(9), 505–513 (2002).
  • Malik N, Gunn J, Shepherd L, Crossman DC, Cumberland DC, Holt CM. Phosphorylcholine-coated stents in porcine coronary arteries: in vivo assessment of biocompatibility. J. Invasive CardioL 13(3), 193–201 (2001).
  • Lewis AL, Stratford PW. Phosphorylcholine- coated stents. J. Long-term Eif Med. Implants 12(4), 231–250 (2002).
  • Whelan DM, van der Giessen W-J, Krabbendam Sc et al. Biocompatibility of phosphorylcholine-coated stents in normal porcine coronary arteries. Heart 83(3), 338–245 (2000).
  • Huang Y, Liu X, Wang L, Verbeken E, Li S, De Scheerder I. Local methylprednisolone delivery using a BiodivYsio phosphorylcholine-coated drug-delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model. Int. J. Cardiovasc. Intervent. 5(3), 166–171 (2003).
  • Liu X, Huang Y, Hanet C et al. STudy of antiRestenosis with the BIodivYsio Dexamethasone-Eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc. Interv. 60(2), 172–178 (2003).
  • •First study of DexametTm in human subjects.
  • Liistro F, Stankovic G, Di Mario C et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 105(16), 1883–1886 (2002).
  • Liu X, Hanet C, Vandormael M et al. Long-term follow-up from the STRIDE clinical study. Circulation 108(Suppl. IV), (2003) (Abstract 2607).
  • Morice MC, Serruys PW, Sousa JE et al. RAVEL Study Group. Randomized study with the sirolimus-coated BX velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl. J. Med. 346(23), 1773–1780 (2002).
  • Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl. J. Med. 349(14), 1315–1323 (2003).
  • Grube E, Silber S, Hauptmann KE et al. TAXUS I: 6- and 12-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107(1), 38–42 (2003).
  • Gershlick A, De Scheerder I, Chevalier B et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 109(4), 487–493 (2004).

Websites

  • American Heart Association website www.amhrt.org (Accessed August 2004)
  • De Scheerder I. Targeting inflammation with drug-eluting stents to reduce restenosis (2003) www.tctmd.com(Accessed August 2004)
  • •• Provides a dynamic web-based community for interventional cardiologists.
  • De Scheerder I. Abbott dexamethasone-eluting stent: from STRIDE to the real-world SAFE registry (2003) www.tctmd.com (Accessed August 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.